New Osteoporosis Drug Launched in Japan
For our readers in Japan good news has arrived over the approval of teriparatide, known in the U.S. as Forteo®, for the treatment of high-risk patients with osteoporosis. The drug is being marketed as TeriboneTM and is available as a 56.5 µg subcutaneous (sub q) weekly injection. For those familiar with or who have taken... Read more


